Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

219

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

219 results for “new drugs”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Adding New Drugs for HIV Infected Patients Failing Current Therapy

ClinicalTrials.gov study NCT00031044. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

ClinicalTrials.gov study NCT00976261. IPD Sharing: Not stated. Countries: 4. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database

ClinicalTrials.gov study NCT06902441. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

ClinicalTrials.gov study NCT00431782. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

ClinicalTrials.gov study NCT04708587. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

ClinicalTrials.gov study NCT04071223. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes

ClinicalTrials.gov study NCT00063583. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

ClinicalTrials.gov study NCT00504556. IPD Sharing: YES. Countries: 12. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

ClinicalTrials.gov study NCT03773393. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
dryad32/100

Data from: Decline in new drug launches: myth or reality? Retrospective observational study using 30 years of data from the UK

Open the record for dataset details and reuse information.

publicFeb 2013View details →
dryad32/100

Data from: Quality of evidence considered by Health Canada in granting full market authorization to new drugs with a conditional approval: a retrospective cohort study

Open the record for dataset details and reuse information.

publicApr 2018View details →
dryad32/100

Data from: How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012

Open the record for dataset details and reuse information.

publicAug 2015View details →
zenodo28/100

Figure 2 from: Abarova S, Stoitchkova K, Tzonev S, Argirova M, Yancheva D, Anastassova N, Tenchov B (2024) Spectroscopic and thermodynamic characterization of the interaction of a new synthesized antitumor drug candidate 2H4MBBH with human serum albumin. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e112385

Figure 2 Fluorescence titration curve of HSA (4 µM) with the 2H4MBBH in saline at 15 °C and 25 °C. Different curves correspond to 2H4MBBH concentrations of 0, 10, 20, 30, 40, 50 µM, respectively.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 3 from: Abarova S, Stoitchkova K, Tzonev S, Argirova M, Yancheva D, Anastassova N, Tenchov B (2024) Spectroscopic and thermodynamic characterization of the interaction of a new synthesized antitumor drug candidate 2H4MBBH with human serum albumin. Pharmacia 71: 1-5. https://doi.org/10.3897/pharmacia.71.e112385

Figure 3 Stern-Volmer plots for quenching of different 2H4MBBH concentrations (10–50 µM) to HSA (4 µM) in saline at 15 and 25 °C.

opencc-by-4.0Jan 2024View details →
zenodo28/100

SNSynergy: similarity network-based machine learning framework for synergy prediction towards new cell lines and new anticancer drug combinations

Open the record for dataset details and reuse information.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Rapid multiplexed nanopore amplicon sequencing to distinguish Plasmodium falciparum recrudescence from new infection in antimalarial drug trials

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2024View details →
dryad28/100

Data from: New sporopollenin-based β-cyclodextrin functionalized magnetic hybrid adsorbent for magnetic solid-phase extraction of nonsteroidal anti-inflammatory drugs from water samples.

A magnetic solid-phase extraction (MSPE) procedure on the newly synthesized magnetic β-cyclodextrin functionalized with toluene diisocyanate (TDI) as a linker and was further modified with bio-polymeric spores of sporopollenin (MSp-TDI-βCD) was developed for the extraction of nonsteroidal anti-inflammatory drugs (NSAIDs) namely indoprofen (INP), ketoprofen (KTP), ibuprofen (IBP) and fenoprofen (FNP) from water samples prior to their HPLC-DAD determination. The newly synthesised MSp-TDI-βCD was comprehensibly characterized using FT-IR, XRD, SEM-EDX, BET and VSM analyses. The separation of selected NSAIDs on MSp-TDI-βCD from aqueous solution was simply achieved by applying an external magnetic field via a permanent magnet. The MSPE parameters affecting extraction performance i.e., sorbent dosage, sample volume, extraction and desorption time, type of organic eluent and volume and solution pH were investigated and optimized. The proposed method showed linear range between 0.5 - 500 ng/mL, low limit of detection at S/N = 3 (0.16 - 0.37 ng/mL) and limit of quantification at S/N = 10 (0.53 - 1.22 ng/mL). The interday (n = 15) and intraday (n = 5) precision for the proposed methods given by relative standard deviation (RSD%) in the range of 2.5 - 4.0 and 2.1 - 5.5 respectively. The extraction recoveries of NSAIDs from environmental samples (tap, drinking and river water) ranged from 92.5 - 123.6%, with satisfactory precision (RSD% less than 12.4%).

opencc-zeroDec 2017View details →
dryad28/100

Dataset for: Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats

<p><span>Many orally administered phenolic drugs undergo enterohepatic recycling (EHR), presumably mediated by the hepatic phase II enzymes. However, the disposition of extrahepatically generated phase II metabolites is unclear. This paper aims to determine the new roles of liver and intestine in the disposition of oral phenolics. 16 representative were tested using direct portal vein infusion and/or intestinal perfusion. The results showed that certain glucuronides were efficiently recycled by liver. OATP1B1/1B3/2B1 were the responsible uptake transporters. Hepatic uptake is the rate-limiting step in hepatic recycling. Our findings showed that the disposition of many oral phenolics is mediated by intestinal glucuronidation and hepatic recycling.<b> </b>A new disposition mechanism "Hepatoenteric Recycling (HER)", where intestine is the metabolic organ and liver is the recycling organ, was revealed. Further investigations focusing on HER should help interpret how intestinal aliments or co-administered drugs that alter gut enzymes (e.g., UGTs) expression/activities will impact the disposition of phenolics. </span></p>

opencc-zeroJul 2021View details →
ClinicalTrials.gov28/100

6-month Intracoronary Optical Coherence Tomography (OCT) Evaluation of Three New Generation Drug Eluting Stent

ClinicalTrials.gov study NCT02850497. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

ClinicalTrials.gov study NCT00127647. IPD Sharing: Not stated. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record